Sign in Subscribe
Pharmaceutical industry

Lpath, Inc. Breaks Ground in Cancer Research with Functional Antibodies Against LPA

Strategic Insights

— 1 min read

Lpath, Inc., a theranostics company, has made a groundbreaking discovery in cancer research by generating functional antibodies against lysophosphatidic acid (LPA), a key bioactive lipid and potent cancer promoter. This achievement marks a significant milestone in the fight against cancer, as LPA has been recognized as a crucial contributor to cancer-cell growth and metastasis. Despite many companies' efforts to produce drugs targeting LPA, Lpath's proprietary ImmuneY2 technology has successfully produced monoclonal antibodies against LPA, demonstrating its potential to mitigate LPA's tumorigenic effects.

Key Takeaways:

  • Lpath, Inc. is the first company to generate functional antibodies against LPA, a key bioactive lipid and potent cancer promoter.
  • The company's proprietary ImmuneY2 technology has successfully produced monoclonal antibodies against LPA.
  • These antibodies have demonstrated the ability to mitigate LPA's tumorigenic effects on cancer cells in standard assays.
  • Lpath has expanded its patent portfolio to include methods and compositions of matter relating to antibodies generated from the ImmuneY2 process, including anti-LPA antibodies.
  • The company's lead product candidate, Sphingomab, has shown preclinical efficacy against six different mouse models of human cancer.
  • Lpath's ability to generate antibodies against bioactive lipids is based on its ImmuneY2 technology, which has the potential to create a pipeline of antibody-based drug candidates.
  • The cancer-related findings were recently published in the scientific journal Cancer Cell.
  • Dr. Gordon Mills, chair of the department of molecular therapeutics at the M.D. Anderson Cancer Center, is excited about the opportunity to evaluate the anti-LPA antibodies in preclinical models of human cancer.
  • Lpath has a strong record of success as a theranostics company, with a focus on bioactive signaling lipids as targets for treating and diagnosing human diseases.

Statistics:

  • 2 decades of research have demonstrated the importance of LPA in cancer.
  • Lpath has generated monoclonal antibodies against LPA using its proprietary ImmuneY2 technology.
  • The anti-LPA antibodies have shown efficacy in preclinical models of human cancer.
  • Lpath has expanded its patent portfolio to include methods and compositions of matter relating to antibodies generated from the ImmuneY2 process.
  • The company's lead product candidate, Sphingomab, has shown preclinical efficacy against seven different forms of human solid-tumor as well as lymphoma and myeloma cancers.
  • The M.D. Anderson Cancer Center has expressed interest in evaluating the anti-LPA antibodies in preclinical models of human cancer.

Sources:

  • Lpath, Inc. press release
  • Health & Medicine Week editors
  • Cancer Cell journal article
  • NewsRx.com article
  • M.D. Anderson Cancer Center

Read more